Nanoporous microparticles 24 Calu-3 cells 25 Andersen cascade impactor 26 Dry powder inhaler 27 2 8 a b s t r a c t 29 In a number of pulmonary diseases, patients may develop abnormally viscous mucus reducing drug effi- 30 cacy. To increase budesonide diffusion within lung fluid, we developed nanoporous microparticles 31 (NPMPs) composed of budesonide and a mucokinetic, ambroxol hydrochloride, to be inhaled as a dry 32 powder. Budesonide/ambroxol-HCl particles were formulated by spray drying and characterised by var- 33 ious physicochemicals methods. Aerodynamic properties were evaluated using a cascade impactor. Drugs 34 apparent permeability coefficients were calculated across mucus producing Calu-3 cell monolayers cul- 35 tivated at an air-liquid interface. Microparticles made only from budesonide and ambroxol-HCl had 36 smooth surfaces. In the presence of ammonium carbonate ((NH 4 ) 2 CO 3 ), NPMPs were formulated, with 37 significantly (P < 0.05) superior aerodynamic properties (MMAD = 1.87 ± 0.22 lm and FPF = 84.0 ± 38 2.6%). The formation of nanopores and the increase in the specific surface area in the presence of (NH 4 ) 2- 39 CO 3 were mainly attributed to the neutralisation of ambroxol-HCl to form ambroxol base. Thus, ambroxol 40 base could behave in the same manner as budesonide and prompt nanoprecipitation when spray dried 41 from an ethanol/water mix occurs. All formulations were amorphous, which should enhance dissolution 42 rate and diffusion through lung fluid. These NPMPs were able to improve budesonide permeability across 43 mucus producing Calu-3 cell monolayers (P < 0.05) suggesting that they should be able to enhance budes- 44 onide diffusion in the lungs through viscous mucus. 45 
Introduction

49
Pharmacotherapy of lung diseases often involves treatment 50 with more than one group of therapeutic agents (e.g., bronchodila-51 tors, corticosteroids, cromoglycate, and antibiotics). In addition to 52 the oral route, these agents are often delivered by pulmonary inha-53 lation, in order to directly target the lung and increase the thera- 54 peutic/systemic side effect index. 55 The local delivery of drugs to the lung can be obtained by using 56 dry powder inhalers (DPIs), metered dose inhalers (MDIs) or neb-57 ulisers. Whenever it is possible, the use of DPIs or MDIs is preferred 58 by patients due to the convenience of use [1, 2] . The simplest for-59 mulation and least problematic, from the point of view of stability, 60 appears to be dry powders due to the presence of the active phar- 61 maceutical ingredient (API) as solid particles and the lack of pro-62 pellant, in contrast to pressurised MDIs, where the API is 63 dissolved or suspended in the liquefied vehicle [3] . Also, in order 64 to improve the results of pharmacotherapy, increase patient 65 compliance and reduce the time of administration of several 66 APIs, co-formulation of drugs into one product [4] [5] [6] [7] or co-67 administration of drugs as a mix of solutions for nebulisation is 68 popular. However, the latter can bring the risk of physicochemical 69 instability of components when mixed extemporaneously [8] . 70 To optimise the efficacy of DPIs, conventional micronised API 71 carrier-based formulations may be substituted by an optimised 72 API powder having specific particle morphology and designed to 73 provide advantageous flow and aerodynamic properties. of two APIs and still be able to maintain the superior aerodynamic 82 properties. 83 BUD was previously reported to form NPMPs when processed 84 by spray drying [11] . BUD is a glucocorticosteroid which, when in-haled, has a dose-dependent anti-inflammatory action in the lung 86 [13]. It acts by binding to glucocorticoid receptors in lung cell cyto-87 plasm [14] . Budesonide has been shown to be very effective against 88 the characteristic inflammation of asthma [15] . It is reported to re-89 duce the risk of Chronic Obstructive Pulmonary Disease (COPD) 90 exacerbations in symptomatic COPD patients [16] . Budesonide also 91 resulted in an improvement in bronchial hyper-responsiveness and 92 a decrease in cough in cystic fibrosis patient [17] . However, in 93 these two last diseases, efficacy of inhaled corticosteroids can be 94 strongly reduced because of the low diffusion through the viscous 95 surface secretions of the lung [18] . In fact, in a number of pulmon-96 ary diseases, patients may develop abnormally high viscous thick 97 mucus which is responsible for low diffusion of drugs in the lungs 98 [5, 19, 20] . 99 To reduce the viscosity of the lung fluid, mucokinetics such as 100 ambroxol hydrochloride (AMB-HCl) are used [21] . Ambroxol may 101 provide suitable rheological properties of the airway secretion by 102 acting directly on ciliated epithelial cells [22] . Ren et al. [23] 103 showed that the rat lung epithelial lining fluid (ELF)/plasma 104 AUC 0?10h ratios obtained for ambroxol hydrochloride (AMB-HCl) 105 after dry powder pulmonary administration were 33-56 times 106 higher compared to those achieved by intravenous administration. A HPLC method, based on the method described by Nolan et al. 178 [11], was set up to assay both BUD and AMB-HCl simultaneously. 179 The assay was performed using a LC module I plus (Waters, UK) 180 chromatographic system equipped with a C18, 15-20 lm, 181 3.9 Â 300 mm apolar column (lBondapak™, Waters, Ireland). Drug with concentration ranging from 0.015 lg/mL to 1 lg/mL. Correla-265 tion coefficient of the calibration curves was higher than 0.99. 266 The apparent permeability (P app ) values in the apical-to-basal 267 direction were calculated using the following equation: Similarly, the specific surface area measured by N 2 adsorption de-291 creased from 6.50 ± 0.14 m 2 /g for C1 to 2.53 ± 0.05 m 2 /g for C4, 292 respectively. When the content of AMB-HCl was held constant 293 (C2, C5, C6 and C4, C7), a small increase in (NH 4 ) 2 CO 3 concentra-294 tion (from 15% to 25% (w/w)) increased the number of pores visible 295 by particles ( Fig. 2: C2, C5 ) and increased the specific surface area 296 from 5.67 ± 0.08 m 2 /g for C2 to 7.14 ± 0.17 m 2 /g for C5, respec-297 tively. However, a larger increase in (NH 4 ) 2 CO 3 concentration 298 (i.e., 35% w/w) produced hollow particles (Fig. 2: C6 and C7) and 299 reduced the specific surface area to 3.91 ± 0.06 m 2 /g for C6. C1  C2  C3  C4  C5  C6  C7  C8  A1  A2  A3   BUD  80  75  70  65  65  55  45  33  95  90  80  AMB-HCl  5  10  15  20  10  10  20  33  5  10 Table 1 . In the presence of (NH 4 ) 2 CO 3 , one diffraction peak at 2h = 32.65°3 20 appeared in the PXRD pattern of the AMB-HCl/(NH 4 ) 2 CO 3 3/7 (w/ 321 w) spray dried system in addition to the diffuse halo ( Fig. 3) . Fig. 4 ). 331 The melting endotherm observed for DSC crystallised BUD 332 shifted to an onset of 260°C. Unprocessed and spray dried 333 AMB-HCl presented similar melting endotherms. DSC scans of 334 AMB-HCl/(NH 4 ) 2 CO 3 3/7 (w/w) spray dried system presented four 335 endotherms having the following temperature onsets: 60, 90, 98 336 and 229°C (Fig. 4) . 337 Formulations made of various BUD/AMB-HCl ratios (A1-A3) 338 presented only a diffuse halo on their PXRD patterns (Fig. 5) . The Table 2 . For all formulations, the percentage of drugs 372 found was close to that calculated on the basis that all the (NH 4 ) 2-373 CO 3 was eliminated. Also the relative amount of AMB-HCl plus 374 BUD was close to 100%, suggesting that most of the (NH 4 ) 2 CO 3 Fig. 5 . PXRD patterns of the formulation as described in Table 1 . was eliminated during the spray drying, and that the particles are 376 mainly composed of BUD and AMB-HCl ( Q2 see Table 3 ). 
Table 3
Measured and theoretical content of BUD and AMB-HCl in the spray dried particles (n = 3 ± SD). Theoretical contents of drugs in the different formulations were calculated on the basis that: (a) all or (b) none of the (NH 4 ) 2 CO 3 was eliminated during the spray drying process. NA (Non-Applicable). 
BUD AMB-HCl
Discussion
414
In order to increase BUD diffusion within abnormally viscous 415 mucus, the co-administration of BUD and AMB-HCl as a dry pow-416 der is of interest. Therefore, our studies aimed to develop highly 417 respirable nanoporous microparticles made of BUD and AMB-HCl. 418 These composite particles were formulated with the aim of 419 enhancing BUD diffusion within thick mucus for a local action 420 and not for a bi-therapy purpose or to enhance BUD systemic 421 absorption. Inhalation therapy results in a high concentration of 422 active drug at the site of action and requires much lower doses 423 than oral administration. As shown by Ren et al. [23] , this is the 424 case for AMB. Therefore, the drug ratios in the present particle 425 compositions were lower than the doses normally used for the 426 individual drugs when used in oral delivery. 427 We previously described the formulation of nanoporous micro- The BUD NPMPs formulated in this previous study were shown 431 to be optimal for pulmonary administration using a DPI as they 432 had high FPF (74.9 ± 3.5%) and good MMAD (2.05 ± 0.10 lm). [30, 31] . Thus, (NH 4 ) 2 CO 3 was incorporated in the 443 formulation in order to overcome this drawback. In fact, (NH 4 ) 2 CO 3 444 is commonly used as a blowing agent [7, 32] , pore-forming agent 445 [32] or process enhancer [10, 11] . This compound decomposes 446 and produces gases during spray drying; thus, it is able to create 447 porous or hollow particles. 448 Most of the composite particles made of BUD and AMB-HCl, for-449 mulated with (NH 4 ) 2 CO 3 , were porous (Fig. 2) . The size and num- lated to its effect on AMB-HCl. 465 Additionally to its capacity to decompose into gases upon heat- 466 ing, (NH 4 ) 2 CO 3 dissolved in water produces a solution composed of 467 HCO À 3 , NH 4 + and NH 3 , with a pH around 9.2. AMB is a weak base 468 having a pK a of 8.05 at 25°C [33] . As a hydrochloride salt, 469 AMB-HCl can react with the HCO À 3 and NH 3 species leading to 470 the formation of AMB base, NH þ 4 , Cl À and H 2 CO 3 as described by 471 the following chemical equilibria. Ethanol is an amphiprotic solvent like water, but having a lower 482 dielectric constant [34] . The apparent ionisation constants (psKa) 483 of base, such as ambroxol, in organic solvent/water mixtures de-484 crease with an increase in organic solvent concentration [35] . 485 Therefore, in the presence of ethanol the chemical reactions de-486 scribed above should be favoured, leading to the formation of 487 AMB base more than in pure water. 488 To support this, DSC scans of AMB-HCl/(NH 4 ) 2 CO 3 3/7 (w/w) 489 spray dried system ( Fig. 4) and of the formulation C1 (Fig. 6 after spray drying AMB-HCl in the presence of (NH 4 ) 2 CO 3 (Fig. 4) , 504 having an onset at 229°C, may correspond to the melting of of (NH 4 ) 2 CO 3 and those of the formulations showed a diffuse halo 524 centred between 2h = 15-22.5°( Fig. 5 ), suggesting the presence of 525 amorphous AMB-HCl. 526 It appears that the presence of AMB base mixed with BUD dur-527 ing the spray drying process was necessary to formulate nanopor- [29] . Furthermore, the FPF of these composite particles was higher 561 than that obtained for the pure BUD NPMP (68.69 ± 1.33%) pre-562 pared by Nolan et al. [11] . 563 For the same initial amount of AMB-HCl of 5% (w/w), the addi-564 tion of (NH 4 ) 2 CO 3 decreased the MMAD and significantly increased 565 the FPF from 72.3 ± 2.5% (A1) to 84.0 ± 2.6% (C1) (Fig. 7) . Thus, the 566 formulation of nanoporous particles improved the particles' aero-567 dynamic properties. An increase in the AMB-HCl content to 14% 568 (w/w) (C5) led to an increase in the MMAD, although it remained 569 in the favourable 1-5 lm diameter range. Interestingly, the FPF re-570 mained high (74.0 ± 2.5%) which could be attributed to the low 571 GSD (1.79 ± 0.03) of this system. This narrow aerodynamic parti-572 cles diameter distribution may presumably result in a good repro-573 ducibility in the dose administered to the patient, which is one of
